<DOC>
	<DOCNO>NCT01036893</DOCNO>
	<brief_summary>This randomize , open-label , two-way cross-over drug-drug interaction Phase I trial . The objective phase I trial investigate healthy female subject : - effect prucalopride absorption ethinylestradiol norethisterone acetate , active constituent several oral contraceptive , first dose prucalopride . - effect multiple oral dose 2 mg prucalopride , 6 day o.d . ( steady state ) , pharmacokinetics ethinylestradiol norethisterone acetate . This trial conduct healthy female child bear potential , i.e . female age 18 45 year ( pre-menopausal ) .</brief_summary>
	<brief_title>M0001 Effects Oral Contraceptive Plasma Levels</brief_title>
	<detailed_description />
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Inclusion criterion Subjects meet follow criterion eligible trial : 1 . Healthy female , age 18 45 year extremes include , regular menstrual cycle 28 Â± 3 day last 6 month . 2 . Adequate use nonhormonal birth control ( doublebarrier method ( e.g . condom spermicide , cervical cap spermicide ) sterilization vasectomy partner certify abstinence ) . 3 . Subjects smoke least 6 month prior selection . 4 . A body mass index ( BMI ) 18 27 kg/m2 , extremes include . 5 . The subject good health base pretrial physical gynaecological examination , medical history , anamnesis , electrocardiogram ( ECG ) result biochemistry , coagulation haematology test urinalysis carry within 4 week start trial . If result biochemistry , coagulation haematology test urinalysis within laboratory 's reference range subject included condition investigator judge deviation clinically significant . 6 . Subjects voluntarily sign write Informed Consent Form ( ICF ) accordance regional law regulation , prior first trial related activity , indicate understand purpose trial . 7 . Subjects willing adhere treatment regimen trial procedure describe protocol . Exclusion criterion Subjects meeting follow criterion exclude trial : 1 . History , evidence suspicion alcohol drug abuse ( screen Day 1 ) . 2 . History evidence cardiac arrhythmia , bronchospastic cardiovascular disease ( e.g . ischemic heart disease cerebrovascular accident ) , hepatic gastrointestinal , renal endocrine ( diabetes mellitus , thyrotoxicosis ) , neurological ( Parkinsonism ) psychiatric , gynaecological dermatological disease , drug allergy . 3 . Clinical significant abnormal ECGintervals morphology ECG , QT &gt; 500 m QTcB &gt; 470 ms. 4 . Use concomitant medication oral contraceptive within 6 week prior screen , hormonal depotdevice within 6 month prior screen . All medication , exception paracetamol stop . 5 . Participation investigational drug trial 30 day prior first visit . 6 . Donation blood 60 day precede first visit . 7 . Pregnancy ( confirm HCG test screen Day 1 treatment session dose ) breast feeding . 8 . Subjects positive result HIV , hepatitis B C screening . 9 . Known allergy trial drug ingredients/excipients . 10 . Subject contraindication use oral contraceptive ( know suspect active venous thromboembolic disorder , know suspect hormone dependent malignancy , undiagnosed vaginal bleeding , coagulation disorder , menstrual cycle depend migraine , lipid metabolism disorder , hepatic disorder )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>